Program
anrikefon
Also written as “HSK21542”, “HSK21542 Injection” and “HSK21542 dose level 1”.
Its studies are mostly in Pruritus · Pain, Postoperative · Renal Insufficiency, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 152 open or running | phase 3since Jan 31, 2021 | Aug 27, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 27, 2019First study: phase 1 study in Pain, PostoperativeFirst studyNCT04110886 · 120 enrolled · Australia
- Dec 25, 2019Phase 1 study in Healthy VolunteersNCT04213196 · 66 enrolled · China
- Jun 3, 2020Phase 2 study in AgnosiaNCT04424251 · 124 enrolled · China
- Jul 7, 20202 phase 2 studiesNCT04470154, NCT04470128
- Jan 31, 2021Phase 3 study in Postoperative AnalgesiaNCT04738357 · 276 enrolled · China
- Aug 4, 2021Phase 2 study in PruritusNCT04999787 · 90 enrolled · China
- Nov 15, 2021Phase 3 study in PruritusNCT05135390 · 545 enrolled · China
- May 12, 2022Phase 3 study in Postoperative AnalgesiaNCT05390905 · 387 enrolled · China
- Apr 19, 2023Phase 1 study in Peripheral Analgesic and Anti-itchNCT05835934 · 6 enrolled · China
- Jun 29, 2023Phase 1 study in Renal InsufficiencyNCT05947097 · 32 planned · China
- Jan 21, 2024Phase 1 study in Chronic Kidney Disease PatientsNCT06238388 · 6 enrolled · China
- Feb 7, 2024Phase 2 study in PruritusNCT06290375 · 250 planned
- Sep 4, 2025Phase 3 study in Postoperative Pain ManagementNCT07186426 · 405 enrolled · China
- Feb 11, 2026Phase 2 study in Postoperative Pain ManagementNCT07442877 · 161 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07442877Postoperative Pain Management · China | 2 | Completed | Jan 24, 2025 | 161 |
| NCT07186426Postoperative Pain Management · China | 3 | Completed | Feb 24, 2026 | 405 |
| NCT06290375Pruritus | 2 | Not yet recruiting | Mar 8, 2024 | 250 |
| NCT06238388Chronic Kidney Disease Patients · China | 1 | Completed | Nov 21, 2023 | 6 |
| NCT05947097Renal Insufficiency · China | 1 | Recruiting | Jul 30, 2023 | 32 |
| NCT05835934Peripheral Analgesic and Anti-itch · China | 1 | Completed | Sep 10, 2021 | 6 |
| NCT05390905Postoperative Analgesia · China | 3 | Completed | Dec 16, 2022 | 387 |
| NCT05135390Pruritus · China | 3 | Completed | Jul 27, 2023 | 545 |
| NCT04999787Pruritus · China | 2 | Completed | Aug 3, 2022 | 90 |
| NCT04738357Postoperative Analgesia · China | 3 | Completed | Jul 30, 2021 | 276 |
| NCT04470154Uremic Pruritus · China | 2 | Completed | Oct 28, 2021 | 131 |
| NCT04470128Agnosia · China | 2 | Completed | Dec 28, 2020 | 180 |
| NCT04424251Agnosia · China | 2 | Completed | Dec 7, 2020 | 124 |
| NCT04213196Healthy Volunteers · China | 1 | Completed | Sep 6, 2020 | 66 |
| NCT04110886Pain, Postoperative · Australia | 1 | Completed | Dec 8, 2020 | 120 |
How it is read
Names in the registry
- “HSK21542”, 14 entries
- “HSK21542 Injection”, 3 entries
- “HSK21542 dose level 1”, 1 entry
- “HSK21542 dose level 2”, 1 entry
- “Experimental: stage I:HSK21542 0.4 μg/kg”, 1 entry
Codes read as this program: HSK21542.
Conditions, from the studies’ own filings
- Pruritus, 4 studies
- Pain, Postoperative, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.